Breath Therapeutics, a Zambon company Information

People living with rare lung disorders are at the center of everything we do. Breath Therapeutics - a Zambon Group Company is a private clinical-stage biopharmaceutical company specializing in advanced inhaled therapies for severe respiratory diseases with high unmet medical need. By combining novel formulations of existing drugs with cutting-edge inhalation technology to rapidly deliver high concentrations of drugs to the site of action in the lung, the company is unleashing the true potential of inhaled drug delivery. This approach increases effective dosing in the lung while minimizing systemic exposure which could lead to new treatment solutions with enhanced efficacy and safety. The Company’s pivotal late-stage program, BOSTON, is evaluating L-CsA-i, the first potential therapy for bronchiolitis obliterans syndrome (BOS), a devastating lung disease with very high mortality that commonly affects patients who have received lung or allogeneic hematopoietic stem cell transplantation. Breath Therapeutics is also evaluating a second clinical development program utilizing its drug-device innovation to address the unmet medical need in additional orphan respiratory diseases. Breath Therapeutics - a Zambon Group Company has offices in Munich, Germany and Menlo Park, CA. For more informationPlease visit https://breath-therapeutics.com/forward-looking-disclaimer/ for forward-looking statements disclaimer.